Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for diabetes and weight loss, according to a review of patient data published on Monday, the ...

SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...

Novo Nordisk (CSE: NOVOb) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened anticipation as the company approaches a pivotal moment in its ...

In recent health news, Chinese scientists stress the need for regional diets to combat obesity, U.S. minority veterans ...

You'll probably recognize their names after seeing them in the news or across social media: Ozempic and Wegovy (made by Novo ...

Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to treat type 2 diabetes. Novo's drugs Ozempic and Wegovy are household names ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

The drugs whose labels were updated include Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro. The agency said, ...

With the rise in the popularity of weight loss drugs like ‘Wegovy’ and ‘Ozempic,’ we’re learning a counterfeit market has ...

Fact checked by Nick Blackmer A recent study found that semaglutide, a GLP-1 weight loss drug, reduced knee pain in people with obesity and knee osteoarthritis.Experts say the reduced knee pain ...